Real-time Analysis of the Biomolecular Interaction Between Gelsolin Andaβ1-42 Monomer and Its Implication for Alzheimer's Disease

Limin Ma,Tian Meng,Yu Wang,Yu Xue,Yuxin Zheng,Jinghuang Chen,Dongming Xu,Jian Sun,Fan Yang,Jianshe Huang,Xiurong Yang
DOI: https://doi.org/10.1016/j.talanta.2024.126938
IF: 6.1
2025-01-01
Talanta
Abstract:Biomolecular interaction acts a pivotal part in understanding the mechanisms underlying the development of Alzheimer's disease (AD). Herein, we built a biosensing platform to explore the interaction between gelsolin (GSN) and different beta-amyloid protein 1-42 (A beta(1-42)) species, including A beta(1-42) monomer (m-A beta), A beta(1-42) oligomers with both low and high levels of aggregation (LLo-A beta and HLo-A beta) via dual polarization interferometry (DPI). Real-time molecular interaction process and kinetic analysis showed that m-A beta had the strongest affinity and specificity with GSN compared with LLo-A beta and HLo-A beta. The impact of GSN on inhibiting aggregation of A beta(1-42 )and solubilizing A beta(1-42) aggregates was evaluated by circular dichroism (CD) spectroscopy. The maintenance of random coil structure of m-A beta and the reversal of beta-sheet structure in HLo-A beta were observed, demonstrating the beneficial effects of GSN on preventing A beta from aggregation. In addition, the structure of m-A beta/GSN complex was analyzed in detail by molecular dynamics (MD) simulation and molecular docking. The specific binding sites and crucial intermolecular forces were identified, which are believed to stabilize m-A beta in its soluble state and to inhibit the fibrilization of A beta(1-42). Combined theoretical simulations and experiment results, we speculate that the success of GSN sequestration mechanism and the balance of GSN levels in cerebrospinal fluid and plasma of AD subjects may contribute to a delay in AD progression. This research not only unveils the molecular basis of the interaction between GSN and A beta(1-42), but also provides clues to understanding the crucial functions of GSN in AD and drives the development of AD drugs and therapeutic approaches.
What problem does this paper attempt to address?